Year of publication
Type of media
Type of material
Licence
Language
1–20 of 153 hits
Sort by:
Sort by:
-
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
Wiley | 2021|Keywords: JAK inhibitor -
Emerging drugs for the treatment of vitiligo
Taylor & Francis Verlag | 2020|Keywords: JAK inhibitor -
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis
Taylor & Francis Verlag | 2020|Keywords: JAK inhibitor -
Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome
Online Contents | 2019|Keywords: JAK inhibitor -
Therapieansprechen der palmoplantaren Pustulose auf Upadacitinib: eine Fallserie von fünf Patienten
Wiley | 2023|Keywords: JAK‐Inhibitor -
Novel topical and systemic therapies in atopic dermatitis
Free accessTaylor & Francis Verlag | 2019|Keywords: JAK inhibitor -
Response of palmoplantar pustulosis to upadacitinib: A case series of five patients
Wiley | 2023|Keywords: jAK inhibitor -
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium
Taylor & Francis Verlag | 2017|Keywords: JAK inhibitor -
Filgotinib for the treatment of Crohn’s disease
Taylor & Francis Verlag | 2018|Keywords: JAK inhibitor -
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
Taylor & Francis Verlag | 2020|Keywords: JAK inhibitor -
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Free accessOnline Contents | 2018|Keywords: JAK inhibitor -
Ruxolitinib is an effective treatment for CALR‐positive patients with myelofibrosis
Wiley | 2016|Keywords: JAK inhibitor -
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia
Free accessTaylor & Francis Verlag | 2022|Keywords: JAK inhibitor -
Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor
Elsevier | 2022|Keywords: JAK inhibitor -
Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib
American Chemical Society | 2022|Keywords: JAK inhibitor -
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis
Wiley | 2022|Keywords: JAK‐inhibitor -
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
Free accessTaylor & Francis Verlag | 2022|Keywords: JAK inhibitor -
Relieving severe itching caused by scabies with tofacitinib: A case report
Free accessWiley | 2023|Keywords: JAK inhibitor
Send my search to (beta)
Send your search query (search terms without filters) to other databases, portals and catalogues to find more interesting hits.
Dimensions:
full data search
or
title and abstract search
Dimensions is a database for abstracts and citations that links information on research funding with the resulting publications, studies and patents.
TIB AV portal
In the TIB AV-Portal, audiovisual media from science and teaching can be foundand own scientific videos can be published.
Specialised Information Service for Mobility and Transport Research (FID move)
Open Research Knowledge Graph (ORKG)
The FID move can be used to search for subject-specific literature, research data and other information from mobility and transport research.
The Open Research Knowledge Graph provides structured descriptions of research content and makes it comparable.
Common Union Catalogue (GVK)
Freely accessible part of the collaborative K10plus catalogue with materials relevant for interlibrary loan and direct delivery services.